Rocket Lab's Two-Speed Reality: Contract Bonanza Meets Neutron's Lingering Question Mark

Rocket Lab posts record revenue and backlog, but Neutron timeline concerns and weak margin guidance weigh on stock despite defense contract wins.

The numbers keep getting bigger, and so does the uncertainty. Rocket Lab's second-quarter 2026 results delivered a record $234 million in revenue and a backlog that swelled to $2.36 billion, yet the stock still slid in after-hours trading. The culprit wasn't the top line — it was the fine print on the company's most anticipated project.

Management guided third-quarter GAAP gross margins to a range of 29 to 31 percent, well shy of the 37.6 percent analysts had penciled in. That shortfall, alongside a wider-than-expected adjusted loss of $0.08 per share, weighed on sentiment despite the revenue beat. But the more consequential revelation concerned Neutron, the heavy-lift rocket that anchors the company's long-term growth thesis.

A Timeline That Keeps Slipping

Rocket Lab now says Neutron will be delivered to the launch pad in the fourth quarter of 2026 — language that Reuters and Bloomberg both interpreted as a de facto delay. The phrasing stops short of confirming an actual launch this year, with the company noting that the production schedule for the stage-one tanks aligns with the current timeline but that the final launch date hinges on qualification tests later in the year.

CEO Peter Beck pushed back on that cautious reading in a Bloomberg television interview on Tuesday, insisting the company is working aggressively toward a first launch before year-end. The tension between Beck's optimism and the more measured language in the quarterly release is unlikely to dissipate quickly. This isn't a new pattern — Neutron has faced repeated delays since 2024, and the January tank failure only added to the skepticism. The concern carries weight because Neutron is the vehicle designed to take on SpaceX's Falcon 9 in the medium-payload segment, and every slip pushes back the monetization of a manifest that already includes multiple firm missions stretching years into the future.

The Counter-Narrative: A Diversifying Business

What makes this moment different from earlier Neutron disappointments is the breadth of activity happening elsewhere in the company. In the span of roughly two weeks, Rocket Lab has stacked up contracts, acquisitions, and infrastructure moves that suggest a growth story no longer tethered to a single rocket.

The company unveiled GHOST, a containerized launch system designed for suborbital and orbital missions from virtually any location, with the Pacific Spaceport Complex in Kodiak, Alaska, as its first site. It also formally established Rocket Lab Germany GmbH, building on the earlier Mynaric acquisition in Munich to expand satellite and component manufacturing for European customers.

The defense pipeline has been particularly active. The US Space Force awarded a $397 million contract under the Space-Based Airborne Moving Target Indicator program, coming just days after Rocket Lab secured a $266 million multi-launch deal — its largest launch contract to date. The company also reported collecting more than $1 billion in new orders for the third quarter since the period began, and a dedicated Neutron launch agreement with Kepler Communications will send multiple satellites for that constellation from Launch Complex 3 on Wallops Island no earlier than 2028.

The smaller Electron system continues to deliver as well. Its 92nd flight on August 6 marked the 13th Electron launch of 2026, deploying the QPS-SAR-13 satellite for Japanese customer iQPS — the eighth mission for that constellation, all of which have succeeded.

What the Chart Says

The stock closed Wednesday at €70.40, up 1.3 percent on the day and 6.8 percent for the week — a recovery that coincides neatly with the early-August announcement wave. Yet the longer view tells a more complicated story. The shares sit 47 percent below their 52-week high of €133.80 from late May, while still trading 91 percent above their level from twelve months ago. The technical picture looks neutral: an RSI of 54.2 puts the stock almost exactly between overbought and oversold territory, with neither euphoria nor panic priced in.

Analysts see meaningful upside from here, with a consensus price target of €96.41 — roughly 37 percent above current levels. The bull case rests on the argument that Rocket Lab is no longer a one-product story, and the recent contract flow from defense and satellite constellations provides a cushion that simply didn't exist a year ago.

The counterweight is the stock's annualized 30-day volatility of 85 percent, a stark reminder that this remains a sentiment-driven, high-beta name where headlines move the price sharply in both directions. The shares' failure to reclaim their May peak suggests the market hasn't fully bought the diversification thesis yet. For now, investors are effectively wagering that the accelerating stream of government and commercial contracts can outpace the reputational and financial damage of yet another Neutron delay. The evidence from this month's deal-making makes that bet look increasingly reasonable — though hardly risk-free.